Could less radiation be safer for kids with neuroblastoma?
NCT ID NCT02245997
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a reduced dose of radiation in 78 children with high-risk neuroblastoma. The goal was to see if a lower dose could still control the tumor while causing fewer long-term side effects. Researchers monitored local control rates and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- external beam radiotherapy (IMRT or proton beam)
- What this could lead to
- If successful, this approach could reduce long-term side effects from radiation in children with high-risk neuroblastoma while still controlling the tumor.
- What could go wrong
- This is a very early-phase trial with only 78 participants, so results may not apply to all patients. Lower radiation might also be less effective at preventing tumor relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
78 people
The number who actually took part.
- Start date
-
Sep 2014
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 months to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must have a diagnosis of neuroblastoma (International Classification of Disease for Oncology \[ICD-O\] morphology 9500/3) confirmed by MSKCC pathologic review * Patients must have high-risk neuroblastoma as defined by the COG Risk Stratification Schema o Patients with International agreement on staging (INSS) stage 4 are eligible with the following: * MYCN amplification, regardless of age or additional biologic features * Age \>18 months, regardless of biologic features OR * Age 1-18 months, with any of the 3 following unfavorable biologic OR features: MYCN amplification, unfavorable pathology, and/or DNA index = 1 o Patients with INSS stage 3 are eligible with the following: * MYCN amplification, regardless of age or additional biologic features OR * Age \> 18 months with unfavorable pathology, regardless of MYCN status o Patients with INSS stage 2a or 2b are eligible with the following: * MYCN amplification, regardless of age or additional biologic features o Patients with INSS stage 4s are eligible with the following: * MYCN amplification, regardless of additional biologic features Patients must have undergone chemotherapy and surgery for high-risk neuroblastoma prior to enrollment on trial. * Age at time of enrollment of ≥1 month and ≤18 years * Female patients of childbearing potential must have a negative pregnancy test within 14 days of radiation start. * Female patients who are lactating must agree to stop breast-feeding. * Sexually active patients of childbearing potential must agree to use effective contraception. Exclusion Criteria: * Patients with gross residual tumor after surgical resection * Patients who have received prior radiotherapy at or adjacent to the primary tumor bed * Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neuroblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart resistant tumors?
- Can a Two-Drug combo outsmart returning childhood cancers?
- Can a Two-Drug combo beat tough childhood cancers?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?